Krüppel-like factor 4 (KLF4) is implicated in all-trans retinoic acid (ATRA)-induced and platelet-derived growth factor-BB (PDGF-BB)-repressed SM22a expression in vascular smooth muscle cells (VSMCs). However, its exact mechanism of action remains unclear. We determined how KLF4 plays different roles in ATRA-and PDGF-BB-dependent regulation of the SM22a gene.
Introduction
Vascular smooth muscle cells (VSMCs) in mature animal vessels are mainly differentiated cells that express smooth muscle (SM)-specific contractile proteins (also referred to as 'SMC marker') SM a-actin, SM-myosin heavy chain (SM-MHC), and SM22a. 1 In response to vascular injury, VSMCs can de-differentiate from a contractile to a synthetic phenotype. 2 Phenotypic switching of VSMCs is a key event in the development of atherosclerosis and restenosis, and involves the coordinated suppression of expression of SMC marker genes. The regulation of VSMC phenotype is complex and involves stimulatory and inhibitory pathways, resulting in the downregulation of SMC marker genes. 3 Despite the importance of VSMC phenotypic switching in the development of vascular diseases, the exact mechanisms controlling VSMC phenotype are not completely understood. 4 Therefore, understanding of the molecular mechanisms regulating VSMC phenotype is helpful for the treatment of vascular proliferative diseases.
The promoter -enhancer region of most SMC marker genes contains common cis-elements, including multiple CC(A/T-rich) 6 GG (CArG) elements and transforming growth factor (TGF)-b control elements, CACCC box, or its reverse orientation sequence. 5, 6 Studies have demonstrated that serum response factor binds to CArG elements and activates the expression of SMC marker genes by cooperating with its cofactors, namely myocardin, MKL1 (MRTF-A), and MKL2 (MRTF-B). 7 Recent studies showed that the zinc finger transcription factor Krüppel-like factor 4 (KLF4) is also implicated in the regulation of the expression of SMC marker genes by directly binding to the TGF-b control element within the promoter -enhancer region of these genes. 8 KLF4 was initially reported to be a potent repressor of SMC marker genes, such as SM a-actin, SM22a, and SM-MHC in cultured VSMCs. 9 Moreover, Owens and coauthor 10, 11 showed that suppression of SMC marker genes by platelet-derived growth factor-BB (PDGF-BB) is mediated (at least in part) by KLF4 interaction with its cis-element. However, recent studies carried out by our research team indicated that overexpression of KLF4 in cultured VSMCs increases the expression of SM22a and SM a-actin, and that knockdown of KLF4 by KLF4-specific small interfering RNA (siRNA) abrogates the inducing effect of all-trans retinoic acid (ATRA) and TGF-b on SMC differentiation. 12, 13 These findings suggest that KLF4 acts as a pro-differentiation factor. As such, the preceding results provide compelling evidence that KLF4 plays a key part in PDGF-BB-induced suppression of SMC marker genes and ATRA-induced activation of SMC marker genes. However, studies investigating the mechanisms by which KLF4 activates or represses the expression of SMC marker genes in the context of ATRA and PDGF-BB are lacking.
In the present study, we aimed to understand how KLF4 plays different roles in ATRA-and PDGF-BB-dependent regulation of the SMC marker gene SM22a.
Methods
The present study was approved by the Institutional Animal Care and Use Committee of Hebei Medical University (Shijiazhuang, China). The study protocol conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication number 85-23, revised 1996).
Cell culture and treatment
VSMCs were isolated from the thoracic aorta of male Sprague -Dawley rats (90 -100 g) as described previously.
14 VSMCs were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco) with 10% foetal bovine serum (FBS) and maintained in 5% CO 2 at 378C in a humidified atmosphere. For ATRA treatment, VSMCs were growth-arrested by incubation in serum-free DMEM for 24 h. The medium was then changed to DMEM containing 5% FBS and 5, 10, or 20 mM ATRA (Sigma-Aldrich). For PDGF-BB treatment, VSMCs were growth-arrested by incubation in serum-free DMEM for 24 h and then treated with 5, 10, or 20 ng/mL PDGF-BB (R&D Systems) for the stated periods. For inhibitor studies, cells were pretreated with the indicated inhibitors (20 mM) for 2 h before the application of 10 mM ATRA and 10 ng/mL PDGF-BB.
Adenovirus expression vector and plasmid constructs
pEGFP-KLF4 and pAd-KLF4 have been described previously. 13 The expression plasmid for p300 was kindly provided by Dr W. R. Harrison (Baylor College of Medicine, Houston, TX, USA). p300-histone acetyltransferase (HAT) (1195-1810) was amplified and subcloned into the pGEX-4T vector. The luciferase reporter plasmid constructs bearing the rat SM22a promoter region are shown in Supplementary material online.
Western blotting
Proteins were isolated from VSMCs as described previously, 15 then separated on sodium dodecyl sulfate -polyacrylamide gel electrophoresis (SDS -PAGE), and transferred onto polyvinylidene difluoride membrane (Millipore). Membranes were blocked with 5% milk in tris-HCl tween buffer solution for 2 h at 378C and incubated overnight at 48C with specific antibodies (the antibodies used are shown in Supplementary material online). After incubation with appropriate secondary antibody, the membranes were developed with the Chemiluminescence Plus Western blot analysis kit (Santa Cruz Biotechnology).
siRNA transfection
siRNAs specific for KLF4 and p38 were synthesized by Sigma-Aldrich (the sequences used are shown in Supplementary material online). Nonspecific siRNA (NS siRNA) and siRNAs specific for rat c-Jun NH 2 -terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and Akt were purchased from Santa Cruz Biotechnology. Transfections were done using Lipofectamine Reagent (Invitrogen) following manufacturer's instructions. Twenty-hours after transfection, VSMCs were treated with ATRA (10 mM) or PDGF-BB (10 ng/mL). Then cells were harvested and lysed for western blotting or co-immunoprecipitation assays.
Luciferase assay
293A cells were purchased from ATCC (Manassas, VA, USA) and maintained in high-glucose DMEM supplemented with 10% FBS. Briefly, cells were seeded in a 24-well plate and grown for 24 h before transfection with KLF4, KLF4 (K225/229R), p300, and pRL-TK plasmids. Cells were transfected using Lipofectamine 2000 (Invitrogen) according to manufacturer's instructions. For VSMCs, 24 h after transfection, cells were treated with ATRA (10 mM) or PDGF-BB (10 ng/mL) for 24 h. Cells were then harvested and luciferase activities were measured using a Dual Luciferase Assay Kit (Promega). Specific promoter activity was expressed as the relative activity ratio of firefly luciferase to Renilla luciferase. All promoter constructs were evaluated in a minimum of three separate wells per experiment.
Chromatin immunoprecipitation (ChIP) assay
VSMCs were cross-linked with 1% formaldehyde for 15 min, lysed as described previously, 16 and then sonicated to an average size of 400 -600 bp. The DNA fragments were immunoprecipitated overnight with anti-KLF4 or anti-mouse IgG (as a negative control). After reversal of cross-linking, the genomic region of the SM22a flanking containing KLF4 binding sites 1 and 2 was amplified by polymerase chain reaction (PCR); the forward and reverse primers used are shown in Supplementary material online.
Oligonucleotide pull-down assay
Oligonucleotide pull-down assay was undertaken as described previously. 17 Oligonucleotides containing KLF4 binding sites 1 and 2 in the rat SM22a promoter with biotin added to their 5 ′ -end are shown in Supplementary material online. Each pair of oligonucleotides was annealed following standard protocols. Cell extracts were precleared with ImmunoPure streptavidin-agarose beads (20 mL/sample, Pierce, Rockford, IL, USA) for 1 h at 48C. After centrifugation for 1 min at 5000 g, the supernatant was incubated with 100 pmol of biotinylated double-strand oligonucleotides and 10 mg of poly (dI-dC) for 16 h at 48C. DNA-bound proteins were collected with 30 mL immobilized streptavidin-agarose beads for 1 h at 48C. They were then washed with lysis buffer four times, separated on SDS -PAGE, and subjected to western blotting.
Co-immunoprecipitation assay
Co-immunoprecipitation was performed as described previously. 18 Cell lysates were immunoprecipitated with anti-KLF4, anti-p300, anti-HDAC2, or anti-acetylated lysine antibodies for 1 h at 48C, followed by incubation with protein A -agarose overnight at 48C. Protein A-agarose-antigenantibody complexes were collected and washed four times with IPH buffer, 20 min each time. Bound proteins were separated on SDS -PAGE, and subjected to western blotting.
In vitro acetylation reactions
Purified GST-KLF4 (300 ng) was incubated with GST-p300-HAT (100 ng) (1195 -1810) in 30 -100 mL HAT buffer (see Supplementary material online) at 308C for 30 min. 19 KLF4 acetylation was then analysed by western blotting using anti-acetylated lysine antibody.
Statistical analyses
Data are mean + SD of at least three independent experiments. Values were subjected to Student's t-test, or one-way ANOVA according to the number of groups compared. Differences were considered significant at P , 0.05.
Results

ATRA and PDGF-BB induce KLF4 expression but exhibit an opposite effect on SM22a expression and VSMC proliferation
Recent works from our research team and that of Owens and coauthor 11, 13 showed that ATRA and PDGF-BB induce KLF4 expression in
VSMCs. ATRA and PDGF-BB exert an opposite regulatory effect on the proliferation and differentiation of VSMCs; so it is reasonable to speculate that KLF4 plays different parts in ATRA-and PDGF-BB-treated VSMCs depending on its interaction partners and post-translational modification.
To test this hypothesis, we first examined the effect of ATRA and PDGF-BB on KLF4 expression and VSMC proliferation. When VSMCs were treated with ATRA or PDGF-BB, VSMC proliferation was significantly inhibited by ATRA and markedly stimulated by PDGF-BB in a dose-dependent manner ( Figure 1A ). We then treated VSMCs with 10 mM ATRA or 10 ng/mL PDGF-BB for different time periods. ATRA time-dependently inhibited VSMC proliferation, whereas PDGF-BB time-dependently stimulated VSMC proliferation.
We tested the effects of ATRA and PDGF-BB on the expression of KLF4 and SMC marker genes to determine whether there is a direct relationship between KLF4 and VSMC phenotypic modulation. Treatment of VSMCs with ATRA and PDGF-BB increased KLF4 expression in a dose-dependent manner ( Figure 1B) . When VSMCs were treated with 10 mM ATRA or 10 ng/mL PDGF-BB at different times, the protein level of KLF4 increased in a time-dependent manner. Interestingly, treating VSMCs with ATRA increased the expression of SM22a and decreased the protein level of PCNA. In contrast, PDGF-BB increased the level of PCNA and decreased the level of SM22a ( Figure 1C ). These results suggest that ATRA and PDGF-BB have opposite effects on VSMC phenotypic modulation, but both increased the expression of KLF4.
KLF4 mediates SM22a expression and promotes the formation of stress fibres
To further verify the role of KLF4 in SM22a expression and formation of stress fibres, we infected VSMCs with pAd-KLF4 or transfected VSMCs with siRNA targeting KLF4 to overexpress or knockdown KLF4 expression. Knockdown of KLF4 blocked the expression of inducible KLF4 by ATRA and PDGF-BB, whereas NS-siRNA had no impact on the expression of KLF4. Correspondingly, we observed a reduction in ATRA-induced SM22a expression and an increase in PDGF-BB-repressed SM22a expression in response to KLF4 silencing ( Figure 2A and B) . Conversely, overexpression of KLF4 markedly increased the expression of SM22a ( Figure 2C ). These results suggest that KLF4 plays a key part in the regulation of SM22a expression by ATRA and PDGF-BB.
SM22a is an actin-binding protein and KLF4 regulates its expression. We therefore sought to determine whether the overexpression or knockdown of KLF4 affected the formation of stress fibres. KLF4 overexpression markedly increased the formation of stress fibres ( Figure 2D ). That is, the actin filaments were recruited into thick and long actin bundles by SM22a. Similarly, ATRA stimulation promoted the formation of stress fibres, whereas PDGF-BB treatment caused a decrease in the formation of actin stress fibres. When KLF4 was knocked down, the formation of actin stress fibres induced by ATRA was reduced, and the decrease in the formation of actin stress fibres induced by PDGF-BB was recovered to some extent ( Figure 2E ). Quantitative intensity analysis further indicates that KLF4 promotes the formation of stress fibres in VSMCs ( Figure 2F ).
ATRA promotes and PDGF-BB represses the binding of KLF4 to the SM22a promoter
The SM22a promoter region from position -676 to +1 contains a typical KLF4 binding site (CACCC) (termed 'site 1') and its reverse orientation sequence (GTGGG) ('site 2') ( Figure 3A) . 9 To investigate the effect of ATRA and PDGF-BB on the binding of KLF4 to sites 1 and 2, the chromatin immunoprecipitation (ChIP) assay was carried out and the SM22a promoter region analysed with two sets of PCR primers that selectively amplify the KLF4 binding site 1 (P1-F and P1-R) or the KLF4 binding site 2 (P2-F and P2-R) ( Figure 3A) . PDGF-BB decreased the binding of KLF4 to site 1 and ATRA increased the binding of KLF4 to site 2 ( Figure 3B) . Consistent with the results of the ChIP assays, oligonucleotide pull-down assay showed that the binding of KLF4 to site 2 was increased by ATRA, whereas the binding to site 1 was decreased by PDGF-BB ( Figure 3C ). KLF4 affinity to sites 1 and 2 was altered upon treatment with ATRA and PDGF-BB; so we sought to determine whether KLF4 binding to the different sites exerts different effects on SM22a promoter activation. We co-transfected VSMCs with the KLF4 expression plasmid and the SM22a promoter (pGL3-SM22a-Luc1) or its mutants of KLF4 binding site 1 or 2 (pGL3-SM22a-Luc3 or pGL3-SM22a-Luc2) ( Figure 3D ). We found that the SM22a promoter containing two KLF4 binding sites (1 and 2) could be activated by ATRA and repressed by PDGF-BB. The response of the SM22a promoter to ATRA was almost completely lost by inactivation of KLF4 binding site 2 when compared with the corresponding control, but the mutation of site 2 did not affect PDGF-BB-induced repression of the SM22a promoter. Conversely, mutation of site 1 did not significantly affect the ATRA-induced activation of the SM22a promoter, but abrogated the PDGF-BB-induced repression of the SM22a promoter when compared with the corresponding control ( Figure 3D ). These results indicate that KLF4 binding sites 1 and 2 are important for SM22a transcription regulated by KLF4, and that site 1 mediates repression by PDGF-BB and site 2 mediates activation by ATRA.
3.4 KLF4 regulates SM22a promoter activity in the context of ATRA and PDGF-BB through different binding sites in an acetylation-dependent manner
Our previous study showed that ATRA increases the acetylation and DNA-binding activity of KLF4. 16 To examine if the different binding of KLF4 to sites 1 and 2 was associated with its acetylation level, we detected the effect of ATRA and PDGF-BB on KLF4 acetylation. VSMCs treated with ATRA or PDGF-BB were grown in medium supplemented with different concentrations of serum; so we first identified that the KLF4 acetylation level was higher in VSMCs grown in a serumfree medium than those grown in medium supplemented with 5% and 10% FBS ( Figure 4A) . ATRA increased and PDGF-BB decreased KLF4 acetylation ( Figure 4B ). Oligonucleotide pull-down assay showed that KLF4 deacetylation caused by PDGF-BB reduced its binding to site 1, whereas KLF4 acetylation induced by ATRA increased its binding to site 2 ( Figure 4C ). KLF4 is acetylated by p300 and regulates gene transcription via modulation of histone acetylation; 20 so we sought to determine the effect of KLF4 acetylation by p300 on SM22a promoter activation. We carried out a reporter gene assay to achieve this. As expected, the co-expression of KLF4 and p300 markedly activated the SM22a promoter containing two KLF4 binding sites. Disruption of KLF4 binding site 1 or 2 did not significantly affect the induction of SM22a by KLF4 and p300. The acetylation-deficient mutant K225/ 229R of KLF4 could not enhance SM22a promoter activity irrespective of whether or not p300 was present ( Figure 4D ). These results suggest that KLF4 acetylation is essential not only for its binding to site 1 but also for its binding to site 2, and that KLF4 acetylation by p300 increases its transactivation function.
We carried out an in vitro acetylation assay to further determine whether the binding activity of KLF4 to sites 1 and 2 is altered by acetylation. First, we confirmed that recombinant GST-KLF4 could be strongly acetylated by GST-p300-HAT in the presence of acetyl-CoA ( Figure 4E) . We then examined, by oligonucleotide pull-down assay, if KLF4 acetylation affects its binding to sites 1 and 2 in vitro. We noted increased binding of acetylated KLF4 to each of the two sites after KLF4 was acetylated ( Figure 4F ). These results indicate that, without ATRA, more KLF4 molecules are non-acetylated and that the binding activity of non-acetylated KLF4 to the site 2 is lower. When VSMCs are treated with ATRA, a certain number of KLF4 molecules are acetylated, and acetylated KLF4 binds to site 2. In contrast, if VSMCs are treated with PDGF-BB, a certain number of KLF4 molecules are deacetylated, and deacetylated KLF4 is dissociated from site 1.
ATRA induces KLF4 acetylation via JNK and p38 pathways, whereas PDGF-BB induces KLF4 deacetylation via ERK and PI3K/Akt pathways
We next examined which signal pathway mediates the acetylation and deacetylation of KLF4 in response to ATRA and PDGF-BB. ATRA increased and PDGF-BB decreased KLF4 acetylation in a timedependent manner ( Figure 5A ). Under these experimental conditions, ATRA dramatically increased the level of phospho-JNK and phospho-p38 but decreased the level of phospho-ERK 15 -30 min after ATRA treatment ( Figure 5B ). The phosphorylation of JNK, p38, ERK, and phosphatidylinositol 3-kinase (PI3K)/Akt was also increased indicates the mutation of KLF4 binding sites. Twenty-four hours after transfection, cells were treated with ATRA or PDGF-BB. Cells were harvested, and luciferase activity determined. Data are mean + SD (n ¼ 3). *P , 0.05 vs. the respective control group. 15 min after PDGF-BB treatment, and this effect persisted until 60 min of PDGF-BB treatment. The expression level of these signal molecules did not change significantly during the course of stimulation with ATRA and PDGF-BB ( Figure 5B) . These results suggest that multiple signal pathways are involved in KLF4 acetylation and deacetylation induced by ATRA and PDGF-BB in VSMCs.
VSMCs were then incubated with the JNK inhibitor SP600125, the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, the ERK inhibitor PD98059, or the PI3K/Akt inhibitor LY294002 for 2 h before exposure to ATRA or PDGF-BB. Inhibition of JNK or p38 blocked the ATRA-induced KLF4 acetylation ( Figure 5C ). Inhibition of ERK and PI3K/Akt blocked the PDGF-BB-induced KLF4 deacetylation, whereas JNK and p38 inhibition had no effect on the KLF4 deacetylation induced by PDGF-BB ( Figure 5D ). To independently confirm these observations, cells were transfected with siRNA targeting JNK, p38, ERK, or Akt and then stimulated with ATRA or PDGF-BB. Under these conditions, acetylation of inducible KLF4 by ATRA and KLF4 deacetylation by PDGF-BB were blocked, consistent with a decrease in the levels of phosphoactive and total forms of JNK, p38, ERK, and Akt ( Figure 5E and F ) .
We carried out an oligonucleotide pull-down assay to further confirm that the acetylation of KLF4 affects its binding to the KLF4 binding sites 1 and 2 on the SM22a promoter. Inhibition of the signalling of JNK or p38 significantly decreased ATRA-induced KLF4 binding to site 2 but did not markedly affect KLF4 binding to site 1 ( Figure 5G) . Conversely, inhibition of signalling by ERK and PI3K/Akt significantly increased the binding of KLF4 to site 1 upon PDGF-BB treatment but had little effect on KLF4 binding to site 2 ( Figure 5G ). Cell lysates were immunoprecipitated with anti-acetylated lysine antibody, followed by brief treatment with 0.5% SDS-containing buffer. The released material was then subjected to oligonucleotide pull-down assay with KLF4 binding site 1 or 2 biotinylated double-stranded oligonucleotides as probes. DNA-bound proteins were collected and analysed by western blotting with anti-KLF4 antibody. (D) 293A cells were co-transfected with expression plasmids for KLF4 or its acetylation-deficient mutant K225/229R and p300 along with the SM22a promoter -reporter plasmid or KLF4 binding site mutants. Twenty-four hours after transfection, cells were harvested, and luciferase activity determined. Data are mean + SD (n ¼ 3).
# P , 0.05 vs.
the respective control group. (E) In vitro acetylation assay; GST-KLF4 and GST-p300-HAT were incubated with acetyl-CoA for 30 min at 308C. KLF4 acetylation was determined by western blotting using an acetylated lysine-specific antibody. (F) After in vitro acetylation, reaction products were pulled down by biotinylated double-stranded oligonucleotides containing KLF4 binding sites 1 and 2, and the binding of acetylated KLF4 to sites 1 and 2 detected by western blotting. . VSMCs were transfected with siRNA targeting JNK, p38, ERK, Akt, or NS-siRNA for 24 h, then treated with ATRA or PDGF-BB (E and F ). Acetylated KLF4 was determined by immunoprecipitation using anti-acetylated lysine antibody and immunoblotting with anti-KLF4 antibody. Phosphorylated and total proteins of JNK, p38, ERK, and Akt are also shown. (G and H ) VSMCs were treated as described earlier, oligonucleotide pull-down assay was done using the probes for KLF4 binding sites 1 and 2, and DNA-bound proteins were analysed by western blotting with anti-KLF4 antibody.
Correspondingly, we observed similar results by siRNA-mediated knockdown of JNK, p38, ERK, or Akt ( Figure 5H ). Taken together, these results further suggest that JNK and p38 pathways mediate ATRA-induced KLF4 acetylation in VSMCs; KLF4 acetylation enhances its binding to site 2; and that the ERK and PI3K/Akt pathways mediate PDGF-BB-induced KLF4 deacetylation and attenuate the binding of KLF4 to site 1 on the SM22a promoter.
3.6 Acetylation of KLF4 requires KLF4 phosphorylation and interaction with p300, and deacetylation of KLF4 requires KLF4 dephosphorylation and interaction with HDAC2
To understand whether ATRA-and PDGF-BB-induced KLF4 acetylation changes are dependent upon KLF4 phosphorylation changes, we first identified that ATRA increased and that PDGF-BB decreased KLF4 phosphorylation in a time-dependent manner ( Figure 6A ). To further determine the signalling pathways leading to changes in the phosphorylation and acetylation of KLF4, we blocked signalling pathways to induce changes in KLF4 acetylation by pharmacological inhibitors and RNA interference. ATRA induced KLF4 phosphorylation via JNK and p38 pathways, and PDGF-BB induced KLF4 dephosphorylation via ERK and PI3K/Akt pathways ( Figure 6B and C). Co-immunoprecipitation assays showed that inhibition of JNK and p38 abrogated ATRA-induced interaction of KLF4 with p300, whereas inhibition of ERK and PI3K/Akt reversed PDGF-BB-repressed interaction of KLF4 with p300. Likewise, reciprocal immunoprecipitation with anti-p300 showed comparable changes in KLF4 co-sedimentation in response to ATRA or PDGF-BB ( Figure 6D) . Further, we demonstrated that ATRA decreased and PDGF-BB increased the levels of HDAC2 present in anti-KLF4 immunoprecipitates. Inhibition of JNK and p38 abrogated ATRA-repressed interaction of KLF4 with HDAC2, and inhibition of ERK and PI3K/Akt abolished PDGF-BB-induced interaction of KLF4 with HDAC2 ( Figure 6D ). Correspondingly, siRNA-mediated knockdown of JNK, p38, ERK, or Akt was accompanied by marked changes in p300 or HDAC2 complexed (C and E) . Phospho-KLF4 was detected as described earlier, and the interaction between KLF4 and p300 or HDAC2 examined by reciprocal immunoprecipitation and western blotting with the indicated antibodies.
with KLF4 when compared with the NS-siRNA ( Figure 6E ). These data suggest that ATRA promotes KLF4 interaction with p300 by inducing KLF4 phosphorylation via JNK and p38 pathways, whereas PDGF-BB promotes KLF4 interaction with HDAC2 by inducing KLF4 dephosphorylation via ERK and PI3K/Akt pathways.
Discussion
PDGF-BB is an important mediator of VSMC phenotypic modulation. 21 ATRA exerts anti-proliferative and pro-differentiation effects in multiple cell types. 22, 23 Recent studies indicate that KLF4
regulates the proliferation and differentiation of VSMCs by multiple mechanisms (including enhancement of p53 expression and regulation of the expression of VSMC marker genes) and is implicated in VSMC phenotypic switching. 24 Interestingly, ATRA and PDGF-BB could induce KLF4 expression, but exhibited an opposite effect on regulation of the SMC marker gene SM22a. We previously demonstrated that KLF4 can directly bind to the promoter of SM22a. 13 However, little is known about the molecular mechanism by which KLF4 induced by ATRA and PDGF-BB exerts different effects on the expression of VSMC marker genes. In the present study, we showed that ATRA activates and PDGF-BB represses SM22a expression through KLF4 binding to, or dissociating from, its different cis-elements in an acetylation-dependent manner. KLF4 is a member of the family of Krüppel-like transcription factors. It binds to a similar DNA sequence that has a CACCC homology or is rich in GC content 25, 26 and exerts biological effects on the proliferation and differentiation of cells in vivo and in vitro. Based on the fact that the SM22a promoter contains a typical KLF4 binding site (CACCC) and its reverse orientation sequence (GTGGG), 13 we constructed SM22a promoter-reporter plasmids containing different KLF4 binding site deletion mutants and analysed their promoter activities under treatments of ATRA and PDGF-BB. We found that KLF4 binding sites 1 and 2 are involved in SM22a transcriptional activation by KLF4. Importantly, we found that site 1 (CACCC) was responsible for transcriptional repression of SM22a by PDGF-BB, and that site 2 (GTGGG) was responsible for transcriptional activation of SM22a by ATRA. As demonstrated in the ChIP and oligonucleotide pull-down experiments, the binding of KLF4 was decreased by PDGF-BB for the CACCC site (site 1). For the GTGGG site (site 2), the binding of KLF4 was increased by ATRA. These findings were consistent with the reporter gene assays in which mutation of site 2 could attenuate the promoter activation by ATRA, and inactivation of site 1 could abolish the promoter repression by PDGF-BB. These results further suggest that site 2 is more important for KLF4 to activate SM22a expression upon treatment of ATRA, and that site 1 is more critical for KLF4 to mediate PDGF-BB-repressed SM22a transcription. Studies have demonstrated that KLF4 acetylation is important for its transactivation, and that KLF4 might function as an activator or repressor of transcription depending upon whether it interacts with co-activators, such as p300 or co-repressors such as HDAC3. 20 Our results showed that ATRA could induce acetylation of KLF4 and that the binding of acetylated KLF4 to site 2 was enhanced, whereas PDGF-BB could promote deacetylation of KLF4 and that the binding of unacetylated KLF4 to site 1 was reduced. These results indicated that ATRA-induced acetylation of KLF4 and PDGF-BB-induced deacetylation of KLF4 altered the binding of KLF4 to its binding sites 1 and 2. These in turn alter the function of KLF4 in SM22a gene regulation in the context of ATRA and PDGF-BB.
It is known that the same transcription factor can reverse function upon signalling-induced modification. 17 Reports revealed that ATRA and PDGF-BB can activate multi-signalling pathways, including MAPKs, PI3K, cAMP-dependent protein kinase A, and protein kinase C. 27, 28 The present study shows that ATRA induced KLF4 acetylation via JNK-and p38-dependent pathways, whereas PDGF-BB promoted KLF4 deacetylation via ERK-and PI3K/Akt-dependent pathways. These data indicated that ATRA-and PDGF-BB-induced phenotypic modulation of VSMCs requires changes not only in the transcription of genes, but also in the function of transcription factors that regulate these genes. Protein phosphorylation is an important mechanism by which a transcription factor recruits co-activators such as phosphorylation of cAMP response element-binding (CREB) protein at Ser133 leading to the recruitment of cAMP response element-binding protein-binding protein (CBP), 29 as well as phosphorylation of KLF5
at the CBP interaction region enhancing its interaction with CBP and its transactivation function. 30 In the present study, we showed that ATRA induced KLF4 phosphorylation and recruitment of p300 via JNK-and p38-dependent pathways, and that PDGF-BB induced dephosphorylation of KLF4 and enhanced the interaction of KLF4 with HDAC2 via ERK-and PI3K/Akt-dependent pathways. The interaction of KLF4 with p300 leads to KLF4 acetylation and SM22a transcriptional activation. Conversely, the recruitment of KLF4 with HDAC2 results in KLF4 deacetylation and suppression of SM22a transcription.
In conclusion, we showed that: (i) ATRA promotes KLF4 acetylation via JNK-and p38-dependent pathways; (ii) acetylated KLF4 activates the SM22a promoter by binding to site 2; (iii) PDGF-BB induces KLF4 deacetylation via ERK-and PI3K/Akt-dependent pathways; and (iv) non-acetylated KLF4 causes suppression of the SM22a promoter by dissociating from site 1. This is the first study to demonstrate that KLF4 can exert different effects on the regulation of SMC marker genes through binding to, or dissociating from, its different cis-elements in an acetylation-dependent manner.
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